
The new alcohol pill Selincro, which is developed and being marketed by Lundbeck and partner Biotie, has made its entry into the British market. The development triggers a milestone payment of 2 million Euros to Biotie.
“Biotie will potentially contribute to Lundbeck towards any required post approval commitment studies. These contributions are not expected to be significant in 2013,” Biotie writes in a press release.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app